FDA Approves Human Trials for Anti-HIV Vaccine

The first and only preventative HIV vaccine based on a genetically modified killed whole virus has received approval by the US FDA to start human clinical trials. Developed by Dr. Chil-Yong Kang and his team at The University of Western Ontario, the vaccine (SAV001) holds tremendous promise; it has already proven to stimulate strong immune responses in preliminary toxicology tests with no adverse effects or safety risks.